Sanofi isn’t the only one hiring, others are hiring too! Check it out! (Isn’t it tempting?)
What’s Sanofi’s answer to the sluggish launch of orphan drug Kynamro (mipomersen)? Put more troops on the ground. ISIS Pharmaceuticals said last Friday during the biotech’s fourth-quarter earnings call that its marketing partner, Sanofi, will add more reps in response to what ISIS COO/CFO Lynne Parshall called a “slow start.” The brand, which was co-developed and is now marketed by Sanofi’s Genzyme unit, was approved in January 2013 for treating HoFH (homozygous familial hypercholesterolemia), a rare cholesterol disorder. Another drug for the same condition, Aegerion’s Juxtapid, was approved the month prior, setting the stage for a rivalry.
Don’t forget, hundreds of biopharma companies are hiring! (We know you can’t resist.)
